Filing Flows › Comparisons › PLX vs DNLI
Protalix BioTherapeutics vs Denali Therapeutics: PLX and DNLI compared
Protalix BioTherapeutics is the larger company: $19.9M of revenue in its latest quarter (Q2 2026) against $17.8M for Denali Therapeutics (Q3 2026). Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -713.0%.
Where the money goes: PLX and DNLI
Protalix BioTherapeutics (PLX) · Q2 2026
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Denali Therapeutics (DNLI) · Q3 2026
Denali Therapeutics, Q3 2026: revenue $17.8M, operating margin -713.0%, net earnings $70.1M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.
| Protalix BioTherapeutics (PLX) | Denali Therapeutics (DNLI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $19.9M | $17.8M |
| Revenue growth, Y/Y | +27% | — |
| Operating margin | 23.5% | -713.0% |
| Net earnings | $3.8M | $70.1M |
| Net margin | 19.0% | 394.5% |
| Operating cash flow | −$10.4M | −$117M |
Where the revenue comes from
Protalix BioTherapeutics
- GOODS: $19.8M (100%)
- LICENSE AND R&D SERVICES: $68K (0%)
Questions
Which is bigger, Protalix BioTherapeutics or Denali Therapeutics?
Protalix BioTherapeutics is the larger company: $19.9M of revenue in its latest quarter (Q2 2026) against $17.8M for Denali Therapeutics (Q3 2026).
Is Protalix BioTherapeutics or Denali Therapeutics growing faster?
Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -713.0%.
More: Protalix BioTherapeutics earnings · how Protalix BioTherapeutics makes money · Denali Therapeutics earnings · how Denali Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.